Explore the words cloud of the IM2PACT project. It provides you a very rough idea of what is the project "IM2PACT" about.
The following table provides information about the project.
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
|Coordinator Country||United Kingdom [UK]|
|Total cost||17˙410˙136 €|
|EC max contribution||9˙000˙000 € (52%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-01-01 to 2023-12-31|
Take a look of project's partnership.
|1||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||coordinator||2˙462˙486.00|
|2||UPPSALA UNIVERSITET||SE (UPPSALA)||participant||1˙113˙250.00|
|3||AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH||AT (WIEN)||participant||582˙292.00|
|4||KOBENHAVNS UNIVERSITET||DK (KOBENHAVN)||participant||532˙198.00|
|5||AARHUS UNIVERSITET||DK (AARHUS C)||participant||483˙966.00|
|6||UNIVERSITY OF DUNDEE||UK (DUNDEE)||participant||354˙008.00|
|7||PHARMACOIDEA FEJLESZTO ES SZOLGALTATO KFT||HU (SZEGED)||participant||300˙058.00|
|8||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||participant||297˙500.00|
|9||CARDIFF UNIVERSITY||UK (CARDIFF)||participant||297˙075.00|
|10||STICHTING VUMC||NL (AMSTERDAM)||participant||290˙437.00|
|11||ARTEMIS BIO-SUPPORT B.V.||NL (DELFT)||participant||290˙380.00|
|12||STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER||DE (HANNOVER)||participant||290˙312.00|
|13||RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG||DE (HEIDELBERG)||participant||290˙187.00|
|14||UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ||DE (Mainz)||participant||288˙661.00|
|15||MIMETAS BV||NL (Leiden)||participant||251˙812.00|
|16||THE UNIVERSITY OF SHEFFIELD||UK (SHEFFIELD)||participant||249˙305.00|
|17||THE OPEN UNIVERSITY||UK (MILTON KEYNES)||participant||232˙283.00|
|18||UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT||DE (WURZBURG)||participant||213˙718.00|
|19||NEUWAY PHARMA GMBH||DE (BONN)||participant||112˙500.00|
|20||UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA||IT (MODENA)||participant||67˙565.00|
|21||FUJIFILM CELLULAR DYNAMICS INC||US (MADISON WI)||participant||0.00|
|22||H. LUNDBECK AS||DK (VALBY)||participant||0.00|
|23||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
|24||NOVARTIS PHARMA AG||CH (BASEL)||participant||0.00|
|25||NOVO NORDISK A/S||DK (BAGSVAERD)||participant||0.00|
|26||PFIZER LIMITED||UK (SANDWICH)||participant||0.00|
|27||SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT||FR (Chilly Mazarin)||participant||0.00|
The overall aim is to further the understanding of the BBB in health and disease states towards the development of innovative brain delivery systems, especially for biopharmaceuticals (e.g., peptides, antibodies, etc.) and the identification of novel disease drug targets (Alzheimer’s Disease, MS, metabolic disease). The related key deliverables will be as follows:
1.Identification and validation of specific genes and/or mechanisms which are altered in brain endothelial cells in disease. 2. Generation, validation and characterisation of robust and predictive iPSC-derived BBB models: The developed models should be more reflective of the in vivo situation than existing models, in the healthy and disease states. 3. New, efficacious and safe mechanisms and technologies of brain delivery: The output of this topic should also result in an expanded and deepened understanding of the fundamental processes that underpin drug-trafficking across the BBB, which in turn can further support endeavours to elucidate novel and more efficacious brain delivery mechanisms. 4. Characterised new genetic models for the diseases of interest in this topic which are better amenable to evaluate disease-modifying agents. 5. Characterised mechanisms of neurotropic virus-mediated BBB and CNS penetration for development of selective brain delivery systems. 6. Established in silico/mathematical models in predicting BBB penetration of therapeutics (such as receptor-or carrier-mediated transcytosis for delivery across the BBB) and pharmacokinetics of biopharmaceutics in different compartments of CNS. 7. Identification of relevant translational readouts which are better amenable to elucidate the role of the BBB in the pathogenesis of neurodegeneration and could eventually lead to new targets for the treatment of the neurovascular causes of the diseases.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IM2PACT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "IM2PACT" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
NOVEL GRAM-NEGATIVE ANTIBIOTIC NOWRead More
Bringing a prophylactic Ebola vaccine to licensureRead More